"10.1371_journal.pone.0039653","plos one","2012-06-22T00:00:00Z","Nathan V Lee; Maruja E Lira; Adam Pavlicek; Jingjing Ye; Dana Buckman; Shubha Bagrodia; Sreesha P Srinivasa; Yongjun Zhao; Samuel Aparicio; Paul A Rejto; James G Christensen; Keith A Ching","Oncology Research Unit, Pfizer Global Research & Development, San Diego, California, United States of America; Global Pre-Clinical Statistics, Pfizer Global Research & Development, San Diego, California, United States of America; Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada; Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada","Conceived and designed the experiments: NVL MEL KAC SS. Performed the experiments: NVL MEL KAC DB. Analyzed the data: NVL MEL AP JY SA KAC. Contributed reagents/materials/analysis tools: KAC AP YZ SA SB. Wrote the paper: NVL MEL KAC JGC PAR SA.","Nathan Lee, Maruja Lira, Adam Pavlicek, Jingjing Ye, Dana Buckman, Shubha Bagrodia, Sreesha Srinivasa, Paul Rejto, James Christensen, and Keith Ching were paid employees of Pfizer. Yongjun Zhao and Samuel Aparicio were funded by Pfizer. Pfizer maintains the patents and marketing rights to the compounds PF-04217903, PF-04880594, and Xalkori used in this study. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","06","Nathan V Lee","NVL",12,TRUE,4,4,6,6,TRUE,TRUE,FALSE,0,NA,FALSE
